4.5 Article

Dehydroepiandrosterone Administration or Gαq Overexpression Induces β-Catenin/T-Cell Factor Signaling and Growth via Increasing Association of Estrogen Receptor-β/Dishevelled2 in Androgen-Independent Prostate Cancer Cells

Journal

ENDOCRINOLOGY
Volume 151, Issue 4, Pages 1428-1440

Publisher

ENDOCRINE SOC
DOI: 10.1210/en.2009-0885

Keywords

-

Funding

  1. National Institutes of Health (Bethesda, MD)

Ask authors/readers for more resources

beta-Catenin/T-cell factor signaling (beta-CTS) plays multiple critical roles in carcinogenesis and is blocked by androgens in androgen receptor (AR)-responsive prostate cancer (PrCa) cells, primarily via AR sequestration of beta-catenin from T-cell factor. Dehydroepiandrosterone (DHEA), often used as an over-the-counter nutritional supplement, is metabolized to androgens and estrogens in humans. The efficacy and safety of unregulated use of DHEA are unclear. We now report that DHEA induces beta-CTS via increasing association of estrogen receptor (ER)-beta with Dishevelled2 (Dvl2) in AR nonresponsive human PrCa DU145 cells, a line of androgen-independent PrCa (AiPC) cells. The induction is temporal, as assessed by measuring kinetics of the association of ER beta/Dvl2, protein expression of the beta-CTS targeted genes, c-Mycandcyclin D1, and cell growth. However, in PC-3 cells, another human AiPC cell line, DHEA exerts no detectible effects, partly due to their lower expression of G alpha-subunits and DHEA down-regulation of ER beta/Dvl2 association. When G alpha q is over-expressed in PC-3 cells, beta-CTS is constitutively induced, including increasing c-Myc and cyclin D1 protein expression. This effect involved increasing associations of G alpha q/Dvl2 and ER alpha/Dvl2 and promoted cell growth. These activities require ER beta in DU-145 and PC-3 cells because they are blocked by ICI 182-780 treatment inactivating ER beta, small interfering RNA administration depleting ER beta, or AR overexpression arresting ER beta. These data suggest that novel pathways activating beta-CTS play roles in the progression of AiPC. Although DHEA may enhance PrCa cell growth via androgenic or estrogenic pathways, the effects of DHEA administration on clinical prostate function remain to be determined. (Endocrinology 151: 1428-1440, 2010)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available